OneShot™ Renal Denervation System

Slides:



Advertisements
Similar presentations
RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???
Advertisements

Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.
EnligHTN™ I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension Vasilios Papademetriou,
The DRASTIC Trial. Dutch Renal Artery Stenosis Intervention Cooperative Reference van Jaarsveld BC, Krijnen P, Derkx FHM, et al. Resistance to antihypertensive.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Steffen Desch Thomas Okon, Diana Heinemann, Konrad Kulle, Karoline Röhnert, Melanie Sonnabend, Martin Petzold, Ulrike Müller, Gerhard Schuler, Ingo Eitel,
CHANGING WORLDS The Impact of University Research.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
PSST 10819_11/2008 Arrhythmia in Practice Today ™ Content provided by Boston Scientific September 2008 Lessons in Lesions.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
A Controlled Trial of Renal Denervation for Resistant Hypertension
Drug Coated Balloons for PAD William B. Newton III, MD Assistant Professor of Surgery Department of Vascular and Endovascular Surgery.
Renal denervation for resistant hypertension: it’s time to reconsider!
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.
Chapter 12 Therapeutic Heating Applications of Radio Frequency Energy C-K. Chou.
Trademarks may be registered and are the property of their respective owners. A reminder that this is a discussion of SYMPLICITY trial results and their.
Renal Sympathetic Denervation View From the EU
Vasilios Papademetriou, MD
The Endocross Enabler-P: First in-Human Results
Meeting of the Balkan Excellent Centers
Prairie Cardiovascular, Springfield, IL US
Prof. Joachim Schofer, MD
Section 4: Managing progression of CKD
The Vessix Global Clinical Program REDUCE-HTN: REINFORCE
Direct Flow Medical Experience with a Conformable, Repositionable, Retrievable, Percutaneous Aortic Valve Reginald Low MD University of California,Davis.
OCT GUIDANCE FOR CTO AVINGER
Thomas F. Lüscher, FESC, FAHA, FRCP
Experimental Studies With a 9 French Forward-Looking Intracardiac Imaging and Ablation Catheter Developed in an NIH Supported Bioengineering Research Partnership.
Potential conflicts of interest
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
Critical Appraisal of the Current Ongoing Study Designs
Innovation Session CRT Meeting Washington, D.C. February 22, 2014
John C. Somberg, MD I have no real or apparent conflicts of interest to report.
From ESH 2016 | POS 7D: Jan Rosa, MD
Renal Denervation Next Steps
Endurant: A New Generation Endograft
Renal Denervation: the St. Jude experience
A Novel “Stent-On-A-Wire”Ultra Low Profile Stent Delivery System
Renal Unit-Careggi University Hospital-Florence-Italy
Accelerating a Revolution in the Treatment of Hypertension
Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.
SMART Study: Sympathetic Mapping/Ablation of Renal Nerves Trial
A randomized controlled trial of distal renal denervation vs conventional mode of the intervention for treatment of resistant hypertension Stanislav Pekarskiy.
Renal Artery Brachytherapy for Sympathetic Renal Denervation for the Treatment of Resistant Hypertension: Preclinical safety study Ron Waksman, Issi Barbash,
A Fixed Guidewire Stent Delivery System
Mapping Sympathetic Nerve Distribution for
Renal CTA: Can We Determine Who Will Benefit from RAS
Chemical Renal Denervation Update and Future Directions
SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: Post Hoc.
Calcified Lesion and Device Intervention Across the Pacific: PMDA View
The XIENCE V EXCEED Study
The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,
The Anglo Scandinavian Cardiac Outcomes Trial
Renal Sympathetic Denervation: The Academic View
CVRx Baroreflex Activation Therapy:
TECHNOLOGY UPDATE TIVUS (Cardiosonic)
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Pre-Clinical Evaluation of Renal Denervation with RF Technologies Meital Mazor, PhD Vessix Vascular, Boston Scientific.
Resistant Hypertension: Initial Combinations of Medications
Renal Denervation Industry Perspective
A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients with Resistant Hypertension (RADIOSOUND-HTN) Philipp Lurz,
Controlling High Blood Pressure
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Controlling Elevated Blood Pressure
Volume 377, Issue 9771, Pages (March 2011)
Clinician Referral Training
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
The Stretta® procedure: device, technique, and pre-clinical study data
Nicolas Mouawad, MD, Chief and Medical Director, Vascular and Endovascular Surgery, McLaren Bay Region A Tale of two lesions.
Presentation transcript:

OneShot™ Renal Denervation System Mark A. Turco, MD, FACC Chief Medical Officer Covidien Vascular Therapies Tuesday February 26, 2013

Mark A. Turco, MD, FACC

The Covidien OneShot™ Irrigated RF Balloon System For Renal Denervation

OneShot™ Renal Denervation System Single-treatment RF ablation per artery reduces procedure time (2 min. total per artery) Spiral electrode design offers standardized and reproducible ablation pattern Integrated irrigation cools the non-treated region of the artery Low pressure, balloon-based system delivered over a standard 0.014" wire

The OneShot System marked by two radiopaque markers for visualization under fluoroscopy 8 evenly-spaced irrigation holes around balloon on either sides of electrode Available in 5mm, 6mm, and 7mm balloon diameters Delivered over a standard .014” guidewire 20mm Low pressure irrigation runs continuously during balloon inflation, providing cooling of the non-treated region of the artery during therapy. The OneShot Renal Denervation System is CE Mark approved.  The OneShot System is not approved for sale in the United States.  

OneShot Generator 6

Fluoroscopy Images During Renal Denervation

Challenging anatomy

RAPID Trial (RApid Renal SymPathetIc Denervation) for chronic resistant hypertension using OneShot™ Objectives: Confirm safety and evaluate effectiveness of OneShotTM for the treatment of chronic resistant hypertension Design: Prospective, single arm, multi-center clinical study Patient Population: Patients diagnosed with documented chronic treatment‐resistant, but stable hypertension and who are treated at or referred to the participating study center are eligible for study screening. Chronic treatment-resistant is defined as systolic blood pressure ≥ 160 mmHg despite treatment with a regimen of 3 or more anti‐hypertensive medications that includes a diuretic Study Size: Enrolled 50 patients with enrollment completed Feb 2013

Non Responders Symplicity HTN II investigaors; The Lancet 2010; 376:1903

Factors Which Impact on Lesion Size Controllable and Known Factors Temperature- / Power-setting Duration of energy application Electrode tip size Irrigation Not controllable / Unknown factors Cooling from cavitary blood flow Electrode-tissue contact Electrode-tissue pressure Electrode-tissue orientation

Energy → Tissue heating RF Ablation – Lesion Formation: Lessons from the EP Docs Energy → Tissue heating therefore ↑ Lesion size ↑ Energy → ↑ Tip temperature ↑ Catheter-tissue interface temperature For Safety: Catheter tip temp should remain  65C to avoid thrombus and charring.

Irrigated RF Treatment - Rationale Irrigated Catheter Active cooling of electrode tip by irrigation fluid Allows use of higher power settings without reaching critically high tip temperatures High power produces larger and bigger lesions Less charring Less thrombus

Summary Aims for new devices for renal denervation: shorter treatment times with a more effective and safer ablation as well as minimizing non responders. The OneShot catheter provides a single ablation over a non compliant 0.014 balloon based platform with continuous irrigation. 21